The prenatal and newborn genetic testing market was valued at US$ 4,034.4 million in 2018 and it is projected to reach US$ 11,204.7 million in 2027; it is expected to grow at a CAGR of 12.2% from 2019 to 2027.
The prenatal and newborn genetic testing market was valued at US$ 4,034.4 million in 2018 and it is projected to reach US$ 11,204.7 million in 2027; it is expected to grow at a CAGR of 12.2% from 2019 to 2027.
Prenatal genetic testing is performed during the pregnancy for the diagnosis of the diseases or detection of specific genetic abnormalities before 8 to 10 weeks of gestation and also helps to determine the sex of the fetus. Most of the prenatal genetic tests use a blood sample from the mother for conduction of various screens. Diagnostic methods are more effective, accurate, and a preferred option for the detection of chromosome abnormalities as compared to the screening methods. The growth of the global prenatal and newborn genetic testing market is attributed to the increase in the prevalence of genetic diseases among infants, supportive government for promoting the use of prenatal and newborn testing and increasing birth rate. However, risk associated with prenatal genetic tests is the major factor hindering the market growth.
The global prenatal and newborn genetic testing market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth.
Request for sample Copy at: https://www.theinsightpartners.com/sample/TIPBT00002550/
Prenatal and newborn genetic testing market Segmentation:
- In terms of product, the global prenatal and newborn genetic testing market is segmented into screening and diagnostics. In 2018, the screening segment held largest share of the market. Also, the same segment is estimated to register the highest CAGR during the forecast period.
- In terms of disease indication, the global prenatal and newborn genetic testing market is segmented into cystic fibrosis, sickle cell anemia, downs syndrome, phenylketonuria and other diseases. In 2018, the down syndrome segment held largest share of the market. However, the cystic fibrosis segment is expected to register the highest CAGR during the forecast period.
- In terms of end user, the global prenatal and newborn genetic testing market is segmented into hospitals & clinics, diagnostic centers and other end user. The hospitals and clinics segment held the largest share of the market in 2018. However, the diagnostics segment is estimated to grow at the fastest rate during the forecast period.
- Some of the prominent players operating in prenatal and newborn genetic testing market are, Abbott, Quest Diagnostics Incorporated, Ravgen, Bio-Rad Laboratories, Inc., Illumina, Inc., F. Hoffmann La-Roche Ltd., Qiagen, Berry Gene, PerkinElmer, Inc., Natera, Inc., and Laboratory Corporation of America Holdings (Sequenom) among others. The market players are focused on bringing new and innovative products and services through various inorganic strategies such as acquisitions and mergers to sustain their position in the market. For instance, in September 2016, Laboratory Corporation of America (LabCorp) completed the acquisition of Sequenom, a genetic diagnostic company that offers diagnostic testing applications as well as genetic analysis products. LabCorp aims to establish a footprint into the prenatal and genetic diagnostic testing market through this acquisition.
High Prevalence of Genetic Diseases in Infants to Drive Global Prenatal and Newborn Genetic Testing Market Growth
Several types of genetic diseases affect the fetuses in the womb. The way in which these genetic diseases are inherited helps to determine the risk that they pose on pregnancy as well as the risk of its recurrence. The risk of having genetic diseases in babies is high in cases where the parents have another child with a genetic disease, family history of a genetic disorder, or if either of a parent has a chromosomal abnormality. There is a significant prevalence of genetic diseases among infants. Moreover, these diseases are also responsible for infant mortality across the globe. For instance, according to the World Health Organization 2016, an estimated 7.9 million infants across world are born with genetic defects. Moreover, according to the Centers for Disease Control and Prevention (CDC), birth defects affects every 1 in 33 babies born in the US. On the other hand, chromosomal abnormalities such as Down syndrome affects 1 in 691 babies born in the US, as per the CDC’s data in 2017.
On the other hand, a survey conducted by John Hopkins University in 2015 states that approximately 20-30% of infant deaths are a result of genetic disorders. Some of the major genetically determined metabolic diseases include sickle cell anemia, phenylketonuria, thalassemia, and others. Down syndrome is the most common chromosomal disorder that affects around 6000 babies in the US, according to the CDC’s statistics. Moreover, according to a report published by Stanford’s Children Health in 2018, sickle cell anemia occurs in almost 1 out 365 black African-American births. Thus, the high prevalence of genetic diseases among infants account for the increasing demands for prenatal and newborn genetic tests, thereby contributing to the growth of the market.
Purchase a copy of the report @ https://www.theinsightpartners.com/buy/TIPBT00002550/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.
Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com